tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
US Market
SYRE
Spyre Therapeutics
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Advertisement

Spyre Therapeutics (SYRE) Stock News & Sentiment

Compare
463 Followers
Spyre Therapeutics: A Promising Buy in the IBD Market with Innovative Combination Biologics and Strategic Milestones
Premium
Ratings
Spyre Therapeutics: A Promising Buy in the IBD Market with Innovative Combination Biologics and Strategic Milestones
5d ago
SYRE
Positive Phase 2 Data from APGE Bolsters Spyre Therapeutics’ Strategy and Stock Appeal
Premium
Ratings
Positive Phase 2 Data from APGE Bolsters Spyre Therapeutics’ Strategy and Stock Appeal
24d ago
SYRE
Spyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
Premium
Ratings
Spyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
1M ago
SYRE
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
Premium
Ratings
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
1M ago
SYRE
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
Premium
Ratings
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
2M ago
SYRE
Spyre Therapeutics Announces Positive Phase 1 Results
Premium
Company Announcements
Spyre Therapeutics Announces Positive Phase 1 Results
2M ago
8K
SYRE
Spyre Therapeutics’ Promising TL1A Program and Undervalued Potential in IBD Market
Premium
Ratings
Spyre Therapeutics’ Promising TL1A Program and Undervalued Potential in IBD Market
2M ago
SYRE
More SYRE News >

SYRE News on the Web

Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 5.81%
AAII
Neutral
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 5.32%
AAII
Neutral
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 5.42%
AAII
Neutral
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 6.20%
AAII
Neutral
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE)
TipRanks News
Neutral
Evercore ISI Sticks to Their Buy Rating for Spyre Therapeutics (SYRE)
TipRanks News
Neutral
JonesTrading Keeps Their Hold Rating on Spyre Therapeutics (SYRE)
TipRanks News
Neutral
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Down 8.73%
AAII
Neutral

News Score - Last 7 Days

Neutral
SYRE
Sector Average
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
This Week59%
Sector Average55%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SYRE’s Media Buzz Sentiment?
Currently, no data Available
What is SYRE’s weekly average amount of articles?
Currently, no data Available
What is SYRE’s News Sentiment?
59% of articles about SYRE were positive this week, compared to its sector average of 55%.
    Healthcare Stocks that are Trending in the News
    SPOKSpok Holdings
    AMRXAmneal Pharmaceuticals
    CRMDCormedix
    KNSAKiniksa Pharmaceuticals
    ANIPANI Pharmaceuticals
    Showing the stocks with the most bullish news sentiment over the past week

    Become an Expert with TipRanks Premium

    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis
    Subscribe NowSee Plans & Pricing